Lucibel risk profile
88 Acute at or past the historical limit
Measured 2 September 2026 from ALUCI's filed statements. Recomputed nightly.
88 (Acute), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 85 | Acute | Stable | Drawdown from the 52-week high — 74.8% |
| Operating pressure | 75 | Stretched | Worsening | Costs outgrowing revenue — +27.3 percentage points |
| Cash conversion | 100 | Acute | Worsening | Capital spending against operating cash — -0.50x |
| Leverage and coverage | 95 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 91 | Acute | Stable | Operating-margin gap against peers — -34.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.